Protocol - Hepatitis B - Assay
Description
This protocol provides instructions for drawing, processing, and storing blood for hepatitis B (HBV) from the National Health and Nutrition Examination Survey (NHANES). As multiple tests must be performed to make the most accurate diagnosis of HBV, the protocol also provides basic guidelines to aid comparability among different studies. Toolkit users are referred to the U.S. Food and Drug Administrations (FDAs) approved laboratory assays.
Specific Instructions
Availability
Protocol
The following is a summary version of the full National Health and Nutrition Examination Survey (NHANES) 2007–2008 protocol.
Exclusion Criteria
Persons will be excluded from this component if they:
- report that they have hemophilia, or
- report that they have received cancer chemotherapy in the last 4 weeks.
SP = Sample Person
1. Do you have hemophilia?
1[ ]Yes
2[ ]No
7[ ]Refused
9[ ]Dont Know
If the SP answers "Yes," the SP is excluded from the blood draw.
If the SP answers "No" or "Dont Know," blood is drawn from the SP.
2. Have you received cancer chemotherapy in the past 4 weeks, or do you anticipate such therapy in the next 4 weeks?
1[ ]Yes
2[ ]No
7[ ]Refused
9[ ]Dont Know
If the SP answers "Yes," the SP is excluded from the blood draw.
If the SP answers "No" or "Dont Know," blood is drawn from the SP.
Note from the Infectious Diseases and Immunity Working Group (WG): The investigator should record the reason a person is excluded from the blood draw.
Venipuncture Procedures
Editors Note: Please review chapter 4 of the Laboratory Procedures Manual from the NHANES for a full description of phlebotomy procedures: 2007-2008 NHANES Lab Manual.
Venipuncture should generally be performed using the median cubital, cephalic, or basilica veins in the left arm unless this arm is unsuitable. If the veins in the left arm are unsuitable, look for suitable veins on the right arm. If the veins in the antecubital space on both arms are not suitable, then look for veins in the forearm or dorsal side of the hand on the left arm/hand and then right arm/hand.
Recording the Results of the Venipuncture Procedure
Immediately after completing the venipuncture, record the results of the blood draw, the reasons for a tube not being drawn according to the protocol, and any comments about the venipuncture.
Note from the Infectious Diseases and Immunity WG: The Infectious Diseases and Immunity WG recommends that the investigator record whether the blood was drawn and whether the full amount was obtained.
Process the Sample for the Serum
Editors Note: Please review chapter 8 of the Laboratory Procedures Manual from the NHANES 2007–2008 for a full description of blood processing procedures: 2007-2008 NHANES Lab Manual.
- Allow the blood to clot by setting aside for 30–45 minutes at room temperature. Do not clot for more than 1 hour.
- Centrifuge the tube at room temperature to separate the serum and aliquot into an appropriate storage tube.
- Determine if the serum is hemolyzed, turbid, lipemic, or icteric. If so, enter a comment to describe the plasma.
Laboratory Assay for Hepatitis B
There are now many laboratory assays that have been approved by the U.S. Food and Drug Administration (FDA). The Infectious Diseases and Immunity WG recommends that Toolkit users review the FDAs Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays to determine the appropriate assay for hepatitis B (HBV) testing. Once an assay is chosen for a particular study, the WG recommends that consistent methods are followed so that assay results will be comparable.
To aid in comparability, the Infectious Diseases and Immunity WG recommends that the investigator record the make and manufacturer of equipment used and the repeatability and coefficients of variation for the assay.
Personnel and Training Required
Phlebotomist
Laboratory capable of performing hepatitis B assay
Equipment Needs
Phlebotomy supplies
Requirements
Requirement Category | Required |
---|---|
Major equipment | No |
Specialized training | No |
Specialized requirements for biospecimen collection | No |
Average time of greater than 15 minutes in an unaffected individual | No |
Mode of Administration
Bioassay
Lifestage
Child, Adult
Participants
Children and adults, aged 2 years and older.
Selection Rationale
The National Health and Nutrition Examination Survey (NHANES) 2007–2008 protocol was selected as the best standardized methodology for blood collection, processing, and storage. Hepatitis B has been measured in the NHANES since 1999.
Language
Chinese, English, Other languages available at source
Standards
Standard | Name | ID | Source |
---|---|---|---|
Logical Observation Identifiers Names and Codes (LOINC) | Assay for hepatitis B proto | 62871-9 | LOINC |
Human Phenotype Ontology | Viral hepatitis | HP:0006562 | HPO |
caDSR Form | PhenX PX160401 - Assay For Hepatitis B | 6185075 | caDSR Form |
Derived Variables
None
Process and Review
Not applicable.
Protocol Name from Source
National Health and Nutrition Examination Survey (NHANES), Laboratory Procedure Manual, 2007 & U.S. Food and Drug Administration (FDAs) approved laboratory assays, 2009
Source
Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS) (2007). National Health and Nutrition Examination Survey Questionnaire. Laboratory Procedures Manual. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
U.S. Food and Drug Administration. Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays. (2009). Accessed September 8, 2010, from http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/
LicensedProductsBLAs/BloodDonorScreening/InfectiousDisease/UCM080466.
General References
Cohen, S. (2007). Acute viral hepatitis. In R. S. Porter & J. L. Kaplan (Eds.), MERCK Manual for Healthcare Professionals. Accessed September 8, 2010, from http://www.merck.com/mmpe/sec03/ch027/ch027b.html#sec03-ch027-ch027b-434.
Weinbaum, C. M., Williams, I., Mast, E. E., Wang, S. A., Finelli, L., Wasley, A., Neitzel, S. M., & Ward, J. W.; Centers for Disease Control and Prevention. (2008). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Morbidity and Mortality Weekly Report, 57(RR-8), 1–20.
Protocol ID
160401
Variables
Export VariablesVariable Name | Variable ID | Variable Description | dbGaP Mapping | |
---|---|---|---|---|
PX160401_Assay_Repeatability | ||||
PX160401080000 | Repeatability of the assay | N/A | ||
PX160401_Blood_Draw_Comments | ||||
PX160401040200 | Record any comments about the blood draw, more | Variable Mapping | ||
PX160401_Blood_Draw_Done | ||||
PX160401040000 | Was blood drawn? | Variable Mapping | ||
PX160401_Blood_Draw_Sample | ||||
PX160401040100 | Was full amount obtained? | N/A | ||
PX160401_Chemotherapy | ||||
PX160401020000 | Have you received cancer chemotherapy in the more | Variable Mapping | ||
PX160401_Coefficient_Of_Variation | ||||
PX160401090000 | Coefficient of variation for the assay | N/A | ||
PX160401_Equipment_Make | ||||
PX160401070100 | Make of the equipment used to perform the more | N/A | ||
PX160401_Equipment_Manufacturer | ||||
PX160401070200 | Manufacturer of the equipment used to more | N/A | ||
PX160401_Exclusion_Criteria | ||||
PX160401030000 | Exclusion Criteria | N/A | ||
PX160401_Hemophilia | ||||
PX160401010000 | Do you have hemophilia? (exclusion from more | Variable Mapping | ||
PX160401_Hepatitis_B_Assay_Results | ||||
PX160401100000 | Hepatitis B assay results | N/A | ||
PX160401_Hepatitis_B_Assay_Type | ||||
PX160401060000 | Record the type of assay used for hepatitis more | N/A | ||
PX160401_Sample_Comments | ||||
PX160401050000 | Record any comments about the sample during more | Variable Mapping |
Measure Name
Hepatitis B Assay
Release Date
November 12, 2010
Definition
This is a bioassay to measure hepatitis B (HBV).
Purpose
The measure determines whether a participant is infected with the hepatitis B virus (HBV). HBV constitutes a major public health problem because of the morbidity and mortality associated with the acute and chronic consequences of this infection. HBV can be spread by blood, bodily fluids, and at childbirth from the mother to the child. HBV infects the liver and can cause scarring (cirrhosis), liver failure, and liver cancer. Because of the high rate of asymptomatic infection, HBV often goes undetected.
Keywords
Infectious disease, Hepatitis B virus, HPV, National Health and Nutrition Examination Survey, NHANES, Infectious Diseases and Immunity
Measure Protocols
Protocol ID | Protocol Name |
---|---|
160401 | Hepatitis B - Assay |
Publications
There are no publications listed for this protocol.